Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACOG vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACOG Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ACOG Overall Winner 6-Pillar Tally: ACOG 3 – 3 BHST Matrix Metrics: ACOG 7 – 3 BHST

As of Nov 20, 2026, Alpha Cognition Inc. (ACOG) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACOG carries a Unified Composite Score of 56.2/100 (HOLD) at $9.00 (26.9x Forward P/E, -141.6% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. ACOG 56.2/100 HOLD), ACOG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-141.6% vs. -18.0% operating margin) and revenue trajectory (+173.8% vs. +3.8% YoY).
  • Technical & Structure Timing Caution: ACOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.6); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACOG vs BHST
ACOG NASDAQ Head-to-Head Winner
Alpha Cognition Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.00
+1.69% 1D
Market Cap $195.1M
TTM Revenue $20M
Forward P/E 26.9x
Beta / 30D Vol 0.75β · 63% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 38.0 Fund 55.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $8.56 · SMA50: $8.66
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (ACOG 3 – 3 BHST)

Columns: Metric · ACOG · BHST
1. Valuation Multiples ACOG
Forward P/E 26.9x N/M
Trailing P/E 26.9x N/M
PEG Ratio N/M N/M
EV / Revenue 9.7x 0.7x
2. Growth & Scale ACOG
Revenue Growth (YoY) +173.8% +3.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $20M $35M
Market Cap $195.1M $29.9M
3. Profitability & Quality BHST
Gross Margin 93.9% 59.0%
Operating Margin -141.6% -18.0%
Net Profit Margin -139.2% -31.2%
Return on Equity (ROE) -67.6% -142.5%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$37M -$9.4M
Cash Flow Margin N/A -26.6%
Net Cash / Leverage $2.24 Book/Sh · -67.6% ROE $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACOG
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 73.3% (50th %ile) N/A (N/A)
Put/Call OI Skew 0.74x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity N/A 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACOG (7) vs BHST (3)
Institutional Metric ACOG BHST Criterion Row Edge
Market Capitalization
Scale
$195.1M $29.9M Larger Scale ACOG
Trailing P/E Ratio
Valuation
26.9x N/M Lower Multiple ACOG
Forward P/E Ratio
Valuation
26.9x N/M Lower Multiple ACOG
Revenue Growth (YoY)
Growth
+173.8% +3.8% Higher Growth ACOG
Operating Margin (TTM)
Profitability
-141.6% -18.0% Higher Margin BHST
Net Profit Margin
Profitability
-139.2% -31.2% Higher Margin BHST
Return on Equity (ROE)
Capital Efficiency
-67.6% -142.5% Higher ROE ACOG
52-Week Range Position
Momentum
80% ($4–$10) 6% ($1–$7) Stronger Trend ACOG
Beta / 30D Volatility
Risk Regime
0.75β · 63% Vol 0.25β · 86% Vol Lower Realized Risk ACOG
Unified Institutional Score
Composite Signal
56.2 / 100 (HOLD) 58.2 / 100 (HOLD) Higher Composite BHST
Trailing 12M Revenue (USD)
Operating Scale
$20M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.9% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.7x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($2.24 Book/Sh · -67.6% ROE) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACOG +30.92 pp
ACOG: +8.3% · BHST: -22.62%
3M Horizon ACOG +28.9 pp
ACOG: -7.69% · BHST: -36.59%
6M Horizon ACOG +120.17 pp
ACOG: +53.85% · BHST: -66.32%
1Y Horizon ACOG +131.43 pp
ACOG: +52.03% · BHST: -79.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACOG Revenue BHST Revenue ACOG Op. Margin BHST Op. Margin Margin Leader
FY2023 N/A $10M N/A -78.6% BHST
FY2024 N/A $30M N/A -27.7% BHST
FY2025 $10M $30M -221.7% -16.2% BHST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACOG CONSOLIDATION
64d in phase · OBV DISTRIBUTION
Current IV 73.3%
IV Percentile 50th %ile
Put/Call OI Skew 0.74x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACOG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $195.1M market capitalization and -141.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ ACOG vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, Alpha Cognition Inc. (ACOG) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACOG carries a Unified Composite Score of 56.2/100 (HOLD) at $9.00 (26.9x Forward P/E, -141.6% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. ACOG 56.2/100 HOLD), ACOG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-141.6% vs. -18.0% operating margin) and revenue trajectory (+173.8% vs. +3.8% YoY). Technical & Structure Timing Caution: ACOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.6); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACOG leads the Growth & Scale pillar: ACOG posts +173.8% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (93.9% gross margin, -141.6% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), ACOG cumulative revenue shifted N/A while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, ACOG deploys N/A (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

ACOG screens cheaper on headline valuation multiples. ACOG trades at 26.9x Forward P/E, 26.9x Trailing P/E, N/M PEG, and 9.7x EV/Revenue (unreported FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACOG (-67.6% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ACOG carries 73.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 0.74x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 63% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.